Inventiva Announces A Late Breaker Abstract And Two Additional Abstracts On Its Lead Compound, Lanifibranor, At The AASLD The Liver Meeting 2023
Portfolio Pulse from Benzinga Newsdesk
Inventiva (NASDAQ:IVA) has announced that its lead compound, Lanifibranor, will be the subject of a late breaker abstract and two additional abstracts at the AASLD The Liver Meeting 2023. The abstracts will present results from phase II trials evaluating Lanifibranor in patients with T2D and MASLD, and patients with NASH. The results show a correlation between the increase of adiponectin under Lanifibranor and the improvement of histological and serum markers of NASH severity. The efficacy of Lanifibranor appears to be independent of PNPLA3 status.
November 06, 2023 | 10:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inventiva's lead compound, Lanifibranor, has shown promising results in phase II trials for the treatment of NASH and T2D. The results will be presented at the AASLD The Liver Meeting 2023, potentially increasing investor interest in the company.
The positive results from the phase II trials of Lanifibranor, Inventiva's lead compound, could increase investor interest in the company. The presentation of these results at a major conference further increases their visibility and could potentially lead to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100